News

Novita Reports Encouraging Phase 2 Trial Results for NP-G2-044

Novita Reports Encouraging Phase 2 Trial Results for NP-G2-044

Positive Phase 2 Trial Results for NP-G2-044 Presented at ASCO

Novita Pharmaceuticals, Inc. is excited to share promising updates from its Phase 2 clinical trial, focusing on NP-G2-044 while presenting at a prominent annual meeting. This innovative treatment demonstrates potential in combination with standard anti-PD-1 therapy for patients fighting advanced solid tumors resistant to previous treatments. The trial results, discussed in a presentation titled "Durable responses in ICI-refractory or acquired resistance: Phase 2 study of NP-G2-044 combined with anti-PD-1 therapy," showcase the therapeutic promise of NP-G2-044 in combating cancer metastasis and improving immune response.

Encouraging Safety and Efficacy Findings

Dr. Jillian Zhang, President & Chief Scientific Officer of Novita, highlighted their satisfaction with the ongoing positive data from the trial. She emphasized that these results underline the potential of their innovative fascin inhibitor to revolutionize treatments for patients with advanced and metastatic solid tumors. With favorable response rates noted, as well as the absence of new metastases in over half of the participants, there's a solid foundation to initiate a Phase 3 study evaluating NP-G2-044 combined with PLD in platinum-resistant ovarian cancer.

Trial Overview and Patient Data

Currently, 45 patients have been administered NP-G2-044, all of whom had previously progressed on anti-PD-1 therapies. With a median of two prior treatment lines, it’s significant that 20% had experienced four or more previous therapies. The selected dosing for NP-G2-044 in combination with anti-PD-1 therapy was 1600 mg QD, measured over four-week intervals. The primary aim of this trial was to determine the objective response rate (ORR), alongside secondary goals including progression-free survival, overall survival, and safety assessments.

Key Findings of the Phase 2 Trial

Here are some of the most notable findings from the trial:

  • A Disease Control Rate of 76%, which incorporates patients with either Stable Disease or positive Objective Responses.
  • The ORR stands at 21%, showcasing three patients achieving Partial Response and four attaining Complete Responses, with two patients exhibiting Pathologic Complete Responses.
  • Durable responses and tumor control were observed across diverse cancer types, demonstrating the effectiveness for at least seven distinct malignancies.
  • Notably, four patients are still receiving ongoing treatment, with two showing response durations exceeding 80 weeks in pancreatic and endometrial cancers.
  • Impressively, 55% of participants did not develop new metastases during the study period.
  • Significant clinical outcomes included sustained Complete Response in cervical cancer, target lesion CR in an endometrial patient, and clinical CRs in others.

Future Directions for Novita's Research

In response to the encouraging results, an amendment to the study is in progress, which aims to incorporate additional cohorts to further examine the effectiveness of NP-G2-044 with anti-PD-1 therapy across varied populations and tumor subtypes. Future analyses will aim to identify biomarkers for predicting responses and understanding resistance mechanisms, promoting personalized treatment approaches for patients facing treatment-resistant cancers. Novita is committed to advancing its research, with plans to reveal further data in the second half of the year and to commence enrollment in its pivotal Phase 3 study for NP-G2-044 + PLD in platinum-resistant ovarian cancer.

About Novita and Fascin Inhibitors

Novita Pharmaceuticals is striving to combat cancer metastasis, the leading cause of cancer-related mortality, by developing innovative fascin inhibitors. These inhibitors target a critical protein that facilitates tumor cell movement, which is overexpressed in tumor cells as well as in cells that present antigens within tumors. The company’s lead candidate, NP-G2-044, has shown a remarkable ability to suppress metastasis in both laboratory and clinical situations. It is also thought to enhance immune responses when combined with existing checkpoint inhibitors, thus providing a dual strategy against cancer.

About Novita Pharmaceuticals, Inc.

Novita Pharmaceuticals, Inc. focuses on pioneering biopharmaceuticals with an emphasis on preventing and treating cancer metastasis through innovative technologies. By advancing therapies that enhance immune responses alongside targeting cancer spread, Novita aims to address existing gaps in cancer treatment. For more information, visit the company's website.

Frequently Asked Questions

What is NP-G2-044?

NP-G2-044 is a fascin inhibitor developed by Novita Pharmaceuticals aimed at targeting metastasis in cancer treatment.

What were the main findings of the Phase 2 trial?

The trial reported a Disease Control Rate of 76%, with 21% achieving objective responses, including complete responses across various tumor types.

What future studies are planned for Novita's research?

Novita plans to expand the study, adding cohorts to evaluate the combination of NP-G2-044 with anti-PD-1 therapy, and explore biomarkers for better treatment predictions.

Who is leading Novita's clinical research?

Dr. Jillian Zhang serves as the President & Chief Scientific Officer, overseeing the research initiatives and the progress of NP-G2-044.

How does NP-G2-044 work in combination with other therapies?

It works by blocking metastasis while potentially enhancing immune responses against tumors when combined with immune checkpoint inhibitors.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

V2’s FOAS Bets on Candid Ad Sales Operator Dialogue

Updated Category News Views 121

Ad sales rarely gets fixed by another ballroom panel, and V2 seems to know it. Its new Future of Ad Sales, or FOAS, forum is built around a simpler premise: put senior operators in a small room, keep vendors and conference theatrics out of the way, and let people compare the ugly real-world details of running revenue machines. Announced November 19, 2026, FOAS is an...

Continue Reading
Goosehead Restatement Puts Accounting Trust on Trial

Updated Category News Views 110

A filing delay can be irritating; a multi-year no-rely warning is something uglier. Goosehead Insurance told investors on November 9, 2026, that it would not timely file its quarterly report for the period ended September 30 and that prior financial statements must be restated. That is not a garden-variety paperwork hiccup. It reaches back across fiscal 2023, 2024 and...

Continue Reading
Neusoft's OneCoreGo Win Puts Auto Software in Focus

Updated Category News Views 65

A Dashboard Award Is Not Just About Pretty Pixels Crystal-like graphics and augmented-reality pathways may sound like the sort of thing a marketing department dreams up after too much coffee, but the more interesting bit in Neusoft's latest news is the machinery underneath. OneCoreGo 7.0 has received the Red Dot Design Award after taking a German iF Design Award earlier...

Continue Reading
MegaRobo's Nearly $200 Million Bet on Learning Labs

Updated Category News Views 115

A lab robot that merely follows instructions is old news; a system that learns from the mess it makes is the expensive part. MegaRobo has raised nearly US$200 million to push toward that harder prize: infrastructure that links AI reasoning to actual experiments, instruments, automation and the results that come back. For investors watching AI for Science, this is more...

Continue Reading
Everyday Dose Tests Coffee in a New Pocket Format Today

Updated Category News Views 0

Coffee has finally wandered into the candy aisle, and I cannot decide whether that is clever or mildly exhausting. Everyday Dose and Austin-based Le Lick have launched Le Latte, a limited-batch coffee-flavored electrolyte lollipop aimed at adults who want caffeine without hauling around a cup. It is an odd little product, sure, but odd is often where consumer brands find...

Continue Reading
Mile High Labs Moves CBD Isolate Into FDA DMF Pathway

Updated Category News Views 39

A Quiet Filing With Real Commercial Weight Cannabis headlines usually arrive wearing a clown suit; this one showed up with paperwork. Mile High Labs says it filed Type II Drug Master File No. 044151 with the U.S. Food and Drug Administration for a 98% CBD isolate on October 2, 2026. That is not a product approval, not permission to market a CBD drug, and certainly not a...

Continue Reading
First Grade Literacy Push Deserves a Harder Look Now

Updated Category News Views 122

A reading gap can become a concrete wall before anyone bothers measuring it. That is the uncomfortable point behind Ignite Reading's First Grade Promise, and it deserves more attention than another polished education announcement usually gets. At a Nov. 5 Convene 2026 gathering in Boston, 56 district and literacy leaders from six states focused on getting children reading...

Continue Reading
Home Values Need More Than an Algorithm and Hope Today

Updated Category News Views 28

A house can look like a clean number on a screen right up until an actual buyer walks through it and notices the tired roof, the sharp kitchen remodel, or the traffic rattling past the front door. That gap between a digital estimate and a real transaction is the whole point of the recent HelloNation discussion featuring Lawton, Oklahoma, real estate experts Pam Marion and...

Continue Reading
RBC Signals Gets $10 Million to Push Space Infrastructure

Updated Category News Views 60

Ground stations are the unglamorous plumbing of the space economy, and somebody finally put fresh capital behind the wrench. RBC Signals says it has received a $10 million strategic growth investment led by Washington Harbour Partners, aimed at enlarging its government-services operation and pushing several newer space-connectivity tools toward commercial use. This is a...

Continue Reading
PBS Holiday Special Bets on Apollo 8, Music and Unity

Updated Category News Views 10

A moon mission, a 360-voice choir, and Christmas television make an unusual bundle, but that is precisely why this year’s Tabernacle Choir special has some real staying power. Peace on Earth: Christmas with The Tabernacle Choir is not trying to chase whatever noisy trend is chewing up attention this week. It is building a 90-minute holiday event around Apollo 8,...

Continue Reading

Top 5 Most Recently Viewed Articles

Aris Mining's Q3 2025 Financial Results Announcement

Updated Category News Views 203

Aris Mining's Q3 2025 Earnings Release Announcement Aris Mining Corporation, known for its commitment to becoming a leading force in the Latin American gold mining sector, has announced its Q3 financial results will be disclosed following market close. This exciting update indicates the company's ongoing transparency and dedication to its stakeholders. Details of the...

Continue Reading
eMazzanti Technologies Celebrates New Office with Ribbon-Cutting

Updated Category News Views 104

eMazzanti Technologies Expands with New Office Space eMazzanti Technologies, a leading Managed Services Provider and Cybersecurity firm, has proudly announced the opening of its new, expansive office located at 724 Clinton Street. This new state-of-the-art office symbolizes their commitment to innovation in technology and workplace solutions. Grand Opening Celebration The...

Continue Reading
Understanding AMC Entertainment's Current Short Interest Trends

Updated Category News Views 969

Understanding AMC Entertainment's Short Interest Trends AMC Entertainment Holdings Inc (NYSE: AMC) has witnessed a notable decline in its short percent of float, dropping 18.42% since its last report. The company recently disclosed that it currently has 37.77 million shares sold short, translating to 9.92% of all available trading shares. Given the stock’s trading...

Continue Reading
Unlocking Asset Growth: CoinEx Launches New Staking Service

Updated Category News Views 83

New Possibilities for CET Holders CoinEx, a global cryptocurrency exchange, has rolled out a Staking service that lets you earn rewards by staking your crypto. With staking, you don’t just collect on-chain rewards—you also help secure the underlying blockchain networks. For many, it’s a practical alternative to traditional investing, with a clear, crypto-native way...

Continue Reading
Market Dynamics: Insights from Experts on Investment Strategies

Updated Category News Views 177

Understanding the Current Market Landscape In today's dynamic market, investors often find themselves seeking clarity in uncertain times. Expert analysts are noting a potential for a significant stock market correction, with some indicating probabilities as high as 30%. This perspective challenges the common assumptions held by many retail investors. The Case for Market...

Continue Reading